@SamMelville16 Great work. I need some advice if you don't mind. My walls have been plasterboarded, wallpapered, and then lining paper on top and painted. Lining paper joins look terrible and I want it all skimmed. Is it best to strip everything back to brick or is there a cheaper/better way?
The big boys must be getting twitchy now. FDA validation of safety/tolerability is hugely significant for the whole platform. They know if they don't strike soon someone else will swoop in. Once the first bid comes in, it'll be all bets are off. 👀 Exciting few months! #AVCT
Chris and her brilliant team continue to build and protect the IP of #AVCT in order to exploit the full value of preCISION for shareholders. honoured to sit on the board of such a disruptive biotech. 2026 will be a transformational year for us all 💥
@PJ_Crabb But CC has already said they need more data for THE RIGHT deal? Investors are desperate so everyone now expects it and are disappointed when it doesn't happen. I'm sure you'd complain if they went to the conference and they didn't tweet about it so they can't win!
Investors moaning about Avacta going to a huge industry conference 😂 what gives. Imagine the anger if they weren't attending! Just sit back and let CC do her job. I have full faith she'll deliver, these phases are part of the journey. Sit back and chill, or move on 🤷♂️ #AVCT
In this video presentation, CEO Chris Coughlin and CMO David Liebowitz provide an update for investors on the Phase 1a data for faridoxorubicin presented at the European Society of Medical Oncology Annual Congress. https://t.co/2qjXF1uOse #AVCT
ESMO results discussion coming soon! I am so happy to introduce you to Dave Liebowitz, MD PhD our chief medical officer who will discuss our ESMO results shortly.
See you in just a bit of time!
Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION platform at the European Society of Medical Oncology Annual Congress. https://t.co/6OX5M6jqHr #AVCT#ESMO25
We are nine games into the season, we have won 7, drawn 1, and lost 1. We have won our opening two Champions League matches without even conceding a goal. We have kept six clean sheets and scored 18 goals. We are second in the table, having already played at Old Trafford, Anfield, St James Park, and Manchester City at home.
We have accomplished all of this while integrating numerous new players and losing key ones, such as Saka, Odegaard, Saliba, and Havertz.
If you're moaning at this, then give your head a wobble. Whilst it hasn't been pretty in some games, we are winning matches, and that's all you should care about. Mikel is cooking, and I'm excited about it.
You can tell Chris is itching to let it out, but simply can't! 😂 The market will have no choice but to start valuing #AVCT appropriately from next month. 👌
@SeanDentBsc@TVR5AVCT@tom_the_bomb__@avacta Sean I think you’ll find this account is just someone representing hundreds of smaller AVCT shareholders who have roughly counted their position via a Telegram group or similar. I’m not sure this is an account from a couple of high net worth individuals.
Getting ready to pop at long last! Tide is finally turning. Looking forward to the next updates on the commercials and scientific side. It’s nice to see the concerns of Heights now firmly in the rear view mirror 👌 #AVCT